Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases.
Data in the literature support the existence of a state of limited metastases or oligometastases. Favorable outcomes have been observed in selected patients with such oligometastases that are treated with local ablative therapies, which include surgical extirpation, stereotactic body radiation therapy (SBRT), and radiofrequency ablation. The role of SBRT in the setting of lymph node oligometastases is still emerging but the early results for local control are promising. However, the biggest challenge is to identify patients who will benefit from treatment of their oligometastatic disease with local aggressive therapy. Patients are initially categorized based upon examination of the initial biopsy, location, stage, and previous treatments received. Appropriate patient management with SBRT requires an understanding of several clinicopathological features that help to identify several subsets of patients with more responsive tumors and a good tolerance to SBRT. In an effort to incorporate the most recent evidence, here the Spanish Society of Radiation Oncology presents guidelines for using SBRT in lymph node oligometastases.
Radiation Oncology, Hospital Provincial de Castellon, Dr. Clara n 19 Ave, Castellon, Spain. antoniojconde@gmail.com.
A J
AJ
Conde-Moreno
Radiation Oncology, University Hospital Virgen del Rocio, Manuel Siurot Ave s/n, 41013, Seville, Spain.
J L
JL
Lopez-Guerra
Radiation Oncology, Salamanca University Hospital, Paseo de San Vicente, Salamanca, Spain.
V A
VA
Macias
Unidad de Oncología Radioterápica, Hospital Meixoeiro-Galaria, Vigo, Hospital Meixoeiro, C/Meixoeiro sn, 36300, Pontevedra, Spain.
M L
ML
Vázquez de la Torre
Oncología Radioterapica, Hospital Universitario Rey Juan Carlos, C/ Gladiolo s/n, Mostoles, Spain.
P
P
Samper Ots
Radiation Oncology, Hospital Quirón Barcelona and Hospital Universitari Quirón Dexeus, Plaza de Alfonso Comín, 5, Barcelona, Spain.
S
S
San José-Maderuelo
Servicio Oncología Radioterápica-ERESA, Hospital General Universitario de Valencia, Avenida Tres Cruces nº2, 46014, Valencia, Spain.
J
J
Pastor Peidro
Servicio Oncología Radioterápica-ERESA, Hospital General Universitario de Valencia, Avenida Tres Cruces nº2, 46014, Valencia, Spain.
J
J
López-Torrecilla
Radiation Oncology, Hospital Universitario Virgen de las Nieves, Av. de las Fuerzas Armadas, 2, Granada, Spain.
J
J
Expósito-Hernández
D002986:Clinical Trials as Topic / Q000592:standards*; D006801:Humans; D008207:Lymphatic Metastasis; D009369:Neoplasms / Q000473:pathology / Q000601:surgery*; D017410:Practice Guidelines as Topic / Q000592:standards*; D011379:Prognosis; D018787:Radiation Oncology / Q000592:standards*; D016634:Radiosurgery / Q000592:standards*; D012955:Societies, Medical; D015996:Survival Rate
Adenopathies; Lymph node oligometastases; Radiosurgery; SABR; SBRT